A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...
Systemic immunotherapy is emerging as a bladder-sparing option for NMIBC, especially for patients unresponsive to BCG therapy ...
Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...
In this discussion, experts review findings from a large real-world dataset comparing clinical outcomes of 2 frontline ...
The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...
Dr. Hinrichs emphasizes the critical need for early referrals and screenings for patients considering advanced cell therapies, enhancing treatment outcomes.
High LAG3 RNA expression in metastatic RCC is associated with improved ORR but not significant OS benefit, indicating adaptive immune resistance. Tumors with high LAG3 levels show robust infiltration ...
Five-year follow-up data from the global, phase 2 JULIET (NCT02445248)trial, which evaluated the chimeric antigen receptor (CAR)T-cell therapy tisagenlecleucel (tisa-cel; Kymriah) in patients with ...
Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...
The process of TIL therapy is complex and requires the coordination of multiple specialties at authorized treatment centers, ...
Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...
The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback